Medicortex Finland Oyj is experiencing exciting times in the following weeks. The company’s majority shareholders (representing approximately 52.9% of the shares) have signed a Share Purchase Agreement (SPA) with the Swedish company Nosium Ab (publ). We are now inviting other shareholders to join the SPA under the same conditions with the majority shareholders – every shareholder will have equal terms.
The acquisition by Nosium is planned to be implemented through a 1:1 share swap, so that a shareholder of Medicortex will receive one new share in Nosium as consideration for each share in Medicortex. Most importantly, at the expected participation rate, Medicortex’s shareholders will reach a majority ownership of about 85% in Nosium. Basically, we take over the votes and power in Nosium, hence the term “reverse takeover” (RTO). Nosium brings to the table the structure and practises of a listed company, which gives us a smooth route to listing on the Swedish stock exchange Nordic Growth Market (NGM).
We have sent an e-mail to all shareholders containing instructions on how to deliver a Power of Attorney (PoA) to participate in the SPA. If you did not receive this information, please contact the company immediately. We kindly ask shareholders to respond by 10 December 2025 at the latest. If you have already returned a signed PoA, we thank you for your contribution. In addition, please inform us of any changes to your contact details so that you can receive updates and communications from the company promptly.
Our mission
Medicortex Finland Oyj, founded in 2014 in Turku, develops diagnostics and treatments for Traumatic Brain Injury (TBI). TBI is commonly caused by falls, traffic accidents, contact sports, or combat, and remains a “silent epidemic” due to low awareness. Currently, diagnosis relies on neurological exams and CT/MRI imaging, which often fail to detect mild TBI or concussion—the majority of cases.
Medicortex is developing a rapid, easy-to-use test that detects proprietary biomarkers released after brain injury, using non-invasive urine or saliva samples. These biomarkers have been validated in preclinical studies, demonstrating their potential for TBI detection. The test aims to be reliable, affordable, and reduce unnecessary imaging. It targets a point-of-care market exceeding €3.3 billion, serving hospitals, the military, sports organizations, and private users.
Dr. Adrian Harel
CEO of Medicortex Finland
Contacts and updates to: medicortex@medicortex.fi